Key transaction details
Regenxbio Inc. (NASDAQ: RGNX) Chief Medical Officer Steve Pakola sold 5,124 shares of company stock on March 10, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The sale was executed at $10.35 per share, resulting in a total transaction value of $53,033. The disposition was carried out under a Rule 10b5-1 trading plan. After the sale, Pakola directly holds 247,926 shares of Regenxbio common stock.
The stock was trading at $9.08 at the time of the update, which is below the price at which Pakola executed the sale.
Clinical progress
Separately, Regenxbio disclosed interim results from its Phase I/II AFFINITY DUCHENNE study of RGX-202, the company’s gene therapy candidate for Duchenne muscular dystrophy. The interim data showed improved performance on timed function tests and on the North Star Ambulatory Assessment for trial participants versus external controls, indicating encouraging early signals on functional measures.
Financials and 2025 results
The company reported fourth-quarter revenue of $30.3 million and a fourth-quarter net loss of $61.7 million. For the full year 2025, Regenxbio recorded revenue of $170.4 million alongside a net loss of $193.9 million.
Analyst views and market perception
Several sell-side firms and market strategists provided updated views following the company’s results. Stifel reiterated a Buy rating, highlighting confidence in RGX-202’s potential based on safety and efficacy signals. H.C. Wainwright maintained a Buy rating and set a price target of $30. Clear Street also reiterated a Buy rating, placing a $45 price target while noting the market appears to undervalue the company’s early data strength. Morgan Stanley adjusted its price target to $17 but kept an Overweight rating after revising its financial model following Regenxbio’s 2025 results.
Platform analysis
InvestingPro analysis flagged Regenxbio as appearing on its Most Undervalued list. The InvestingPro Tips included in the platform note call out that the company is burning through cash and remained unprofitable over the last twelve months. The InvestingPro note references six additional ProTips and a comprehensive Pro Research Report that investors can access for more in-depth analysis.
What this means
The insider sale was executed under an established 10b5-1 plan and reduced Pakola’s direct holdings to 247,926 shares. At the same time, Regenxbio’s clinical update and the mixed-but-constructive set of analyst ratings signal ongoing interest from the research community, even as the company reports substantial net losses and continued cash use. The stock trading below the insider sale price highlights a current market valuation that differs from the trade executed.
For investors, the confluence of insider activity, fresh clinical data, persistent cash burn, and divergent analyst price targets frames the near-term narrative for Regenxbio.